Falk Hertwig
Overview
Explore the profile of Falk Hertwig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1747
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grunewald L, Andersch L, Helmsauer K, Schwiebert S, Klaus A, Henssen A, et al.
Pharmacol Res
. 2025 Jan;
212:107608.
PMID: 39828101
Current treatment protocols have limited success against MYCN-amplified neuroblastoma. Adoptive T cell therapy presents an innovative strategy to improve cure rates. However, L1CAM-targeting CAR T cells achieved only limited response...
2.
Sprussel A, Suzuki T, Miyata N, Astrahantseff K, Szymansky A, Toedling J, et al.
J Clin Med
. 2024 Oct;
13(20).
PMID: 39458030
The KDM1A histone demethylase regulates the cellular balance between proliferation and differentiation, and is often deregulated in human cancers including the childhood tumor neuroblastoma. We previously showed that KDM1A is...
3.
Rodriguez-Fos E, Planas-Felix M, Burkert M, Puiggros M, Toedling J, Thiessen N, et al.
Cell Genom
. 2023 Oct;
3(10):100402.
PMID: 37868040
Neuroblastoma is a pediatric solid tumor characterized by strong clinical heterogeneity. Although clinical risk-defining genomic alterations exist in neuroblastomas, the mutational processes involved in their generation remain largely unclear. By...
4.
Fuchs S, Danssmann C, Klironomos F, Winkler A, Fallmann J, Kruetzfeldt L, et al.
Nat Commun
. 2023 Jul;
14(1):3936.
PMID: 37402719
Circular RNAs (circRNAs) are a regulatory RNA class. While cancer-driving functions have been identified for single circRNAs, how they modulate gene expression in cancer is not well understood. We investigate...
5.
Berlak M, Tucker E, Dorel M, Winkler A, McGearey A, Rodriguez-Fos E, et al.
Mol Cancer
. 2022 Jun;
21(1):126.
PMID: 35689207
Background: Development of resistance to targeted therapies has tempered initial optimism that precision oncology would improve poor outcomes for cancer patients. Resistance mechanisms, however, can also confer new resistance-specific vulnerabilities,...
6.
Roderwieser A, Sand F, Walter E, Fischer J, Gecht J, Bartenhagen C, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-20.
PMID: 35100718
Purpose: Telomere maintenance is a hallmark of high-risk neuroblastoma; however, the contribution of telomerase and alternative lengthening of telomeres (ALT) to clinical phenotypes has remained unclear. We aimed to determine...
7.
Schmelz K, Toedling J, Huska M, Cwikla M, Kruetzfeldt L, Proba J, et al.
Nat Commun
. 2021 Nov;
12(1):6804.
PMID: 34815394
Intratumour heterogeneity is a major cause of treatment failure in cancer. We present in-depth analyses combining transcriptomic and genomic profiling with ultra-deep targeted sequencing of multiregional biopsies in 10 patients...
8.
Rosswog C, Bartenhagen C, Welte A, Kahlert Y, Hemstedt N, Lorenz W, et al.
Nat Genet
. 2021 Nov;
53(12):1673-1685.
PMID: 34782764
The mechanisms behind the evolution of complex genomic amplifications in cancer have remained largely unclear. Using whole-genome sequencing data of the pediatric tumor neuroblastoma, we here identified a type of...
9.
Dorel M, Klinger B, Mari T, Toedling J, Blanc E, Messerschmidt C, et al.
PLoS Comput Biol
. 2021 Nov;
17(11):e1009515.
PMID: 34735429
Very high risk neuroblastoma is characterised by increased MAPK signalling, and targeting MAPK signalling is a promising therapeutic strategy. We used a deeply characterised panel of neuroblastoma cell lines and...
10.
Szymansky A, Kruetzfeldt L, Heukamp L, Hertwig F, Theissen J, Deubzer H, et al.
J Pers Med
. 2021 Aug;
11(8).
PMID: 34442335
For many years, the risk-based therapy stratification of children with neuroblastoma has relied on clinical and molecular covariates. In recent years, genome analysis has revealed further alterations defining risk, tumor...